JLE

Hépato-Gastro & Oncologie Digestive

MENU

Skin adverse reactions associated with anti-TNF-alpha Volume 22, issue 8, Octobre 2015

Figures


  • Figure 1

  • Figure 2

  • Figure 3

  • Figure 4

  • Figure 5

  • Figure 6

  • Figure 7
Authors
Hôpital Saint-André,
service de dermatologie et dermatologie pédiatrique,
centre de référence national des maladies rares de la peau,
1 rue Jean Burguet,
33075 Bordeaux Cedex, France
* Tirés à part

Anti-tumor necrosis factor (TNF)α includes both monoclonal antibodies and a recombinant soluble receptor directed against the pro-inflammatory cytokine called TNFα. These biotherapies have profoundly changed the course of inflammatory diseases such as inflammatory bowel diseases (Crohn's disease, ulcerative colitis), inflammatory rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis) and psoriasis. Overall, these therapies are well tolerated. However, with increasing use of these agents, side effects and cutaneous adverse reactions have been reported. Skin reactions associated with anti-TNFα therapies include infectious skin reactions, skin tumors and inflammatory skin disorders. This educative case report aims to illustrate a classical form of skin inflammatory reactions associated with TNFα blockers called psoriasiform eruptions and will review skin inflammatory conditions induced by these biologics.